nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP3A4—bone cancer	0.597	1	CbGaD
Azelastine—CYP2B6—Cisplatin—bone cancer	0.0374	0.255	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—bone cancer	0.0251	0.171	CbGbCtD
Azelastine—CYP2C9—Cisplatin—bone cancer	0.0197	0.135	CbGbCtD
Azelastine—ABCB1—Cisplatin—bone cancer	0.0192	0.131	CbGbCtD
Azelastine—ABCB1—Doxorubicin—bone cancer	0.0128	0.0877	CbGbCtD
Azelastine—ABCB1—Methotrexate—bone cancer	0.0124	0.085	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—bone cancer	0.0121	0.0826	CbGbCtD
Azelastine—CYP3A4—Doxorubicin—bone cancer	0.0077	0.0526	CbGbCtD
Azelastine—Aphthous stomatitis—Epirubicin—bone cancer	0.0015	0.012	CcSEcCtD
Azelastine—Ulcer—Cisplatin—bone cancer	0.00145	0.0116	CcSEcCtD
Azelastine—Furuncle—Epirubicin—bone cancer	0.00144	0.0115	CcSEcCtD
Azelastine—Pain—Carboplatin—bone cancer	0.00143	0.0114	CcSEcCtD
Azelastine—Ulcerative stomatitis—Doxorubicin—bone cancer	0.00141	0.0113	CcSEcCtD
Azelastine—Aphthous stomatitis—Doxorubicin—bone cancer	0.00139	0.0111	CcSEcCtD
Azelastine—Mucosal inflammation—Methotrexate—bone cancer	0.00136	0.0109	CcSEcCtD
Azelastine—Furuncle—Doxorubicin—bone cancer	0.00133	0.0106	CcSEcCtD
Azelastine—Body temperature increased—Carboplatin—bone cancer	0.00132	0.0106	CcSEcCtD
Azelastine—Mucosal inflammation—Epirubicin—bone cancer	0.00127	0.0102	CcSEcCtD
Azelastine—Mucosal inflammation—Doxorubicin—bone cancer	0.00118	0.00943	CcSEcCtD
Azelastine—Parosmia—Epirubicin—bone cancer	0.00109	0.0087	CcSEcCtD
Azelastine—Anaphylactoid reaction—Cisplatin—bone cancer	0.00103	0.00824	CcSEcCtD
Azelastine—Parosmia—Doxorubicin—bone cancer	0.001	0.00805	CcSEcCtD
Azelastine—Laryngitis—Epirubicin—bone cancer	0.000977	0.00783	CcSEcCtD
Azelastine—Face oedema—Cisplatin—bone cancer	0.000961	0.0077	CcSEcCtD
Azelastine—Albuminuria—Epirubicin—bone cancer	0.000943	0.00756	CcSEcCtD
Azelastine—Laryngitis—Doxorubicin—bone cancer	0.000904	0.00724	CcSEcCtD
Azelastine—Nasopharyngitis—Cisplatin—bone cancer	0.00089	0.00713	CcSEcCtD
Azelastine—Albuminuria—Doxorubicin—bone cancer	0.000873	0.00699	CcSEcCtD
Azelastine—Stinging—Epirubicin—bone cancer	0.000869	0.00696	CcSEcCtD
Azelastine—Ageusia—Epirubicin—bone cancer	0.000869	0.00696	CcSEcCtD
Azelastine—Herpes simplex—Methotrexate—bone cancer	0.000817	0.00654	CcSEcCtD
Azelastine—Glossitis—Methotrexate—bone cancer	0.000817	0.00654	CcSEcCtD
Azelastine—Breast pain—Epirubicin—bone cancer	0.000807	0.00647	CcSEcCtD
Azelastine—Stinging—Doxorubicin—bone cancer	0.000804	0.00644	CcSEcCtD
Azelastine—Ageusia—Doxorubicin—bone cancer	0.000804	0.00644	CcSEcCtD
Azelastine—Amenorrhoea—Epirubicin—bone cancer	0.000802	0.00642	CcSEcCtD
Azelastine—Ulcer—Methotrexate—bone cancer	0.000796	0.00637	CcSEcCtD
Azelastine—Viral infection—Epirubicin—bone cancer	0.00078	0.00625	CcSEcCtD
Azelastine—Thinking abnormal—Epirubicin—bone cancer	0.000769	0.00616	CcSEcCtD
Azelastine—Lacrimation increased—Epirubicin—bone cancer	0.000764	0.00612	CcSEcCtD
Azelastine—Herpes simplex—Epirubicin—bone cancer	0.000764	0.00612	CcSEcCtD
Azelastine—Glossitis—Epirubicin—bone cancer	0.000764	0.00612	CcSEcCtD
Azelastine—Breast pain—Doxorubicin—bone cancer	0.000747	0.00598	CcSEcCtD
Azelastine—Conjunctivitis—Cisplatin—bone cancer	0.000746	0.00597	CcSEcCtD
Azelastine—Ulcer—Epirubicin—bone cancer	0.000745	0.00597	CcSEcCtD
Azelastine—Amenorrhoea—Doxorubicin—bone cancer	0.000742	0.00594	CcSEcCtD
Azelastine—Viral infection—Doxorubicin—bone cancer	0.000721	0.00578	CcSEcCtD
Azelastine—Thinking abnormal—Doxorubicin—bone cancer	0.000712	0.0057	CcSEcCtD
Azelastine—Glossitis—Doxorubicin—bone cancer	0.000707	0.00567	CcSEcCtD
Azelastine—Lacrimation increased—Doxorubicin—bone cancer	0.000707	0.00567	CcSEcCtD
Azelastine—Herpes simplex—Doxorubicin—bone cancer	0.000707	0.00567	CcSEcCtD
Azelastine—Dermatitis contact—Epirubicin—bone cancer	0.000696	0.00558	CcSEcCtD
Azelastine—Ulcer—Doxorubicin—bone cancer	0.000689	0.00552	CcSEcCtD
Azelastine—Influenza like illness—Epirubicin—bone cancer	0.000684	0.00548	CcSEcCtD
Azelastine—Mouth ulceration—Methotrexate—bone cancer	0.00068	0.00545	CcSEcCtD
Azelastine—Visual impairment—Cisplatin—bone cancer	0.000664	0.00532	CcSEcCtD
Azelastine—Dermatitis contact—Doxorubicin—bone cancer	0.000644	0.00516	CcSEcCtD
Azelastine—Eye disorder—Cisplatin—bone cancer	0.000644	0.00516	CcSEcCtD
Azelastine—Flushing—Cisplatin—bone cancer	0.000639	0.00512	CcSEcCtD
Azelastine—Mouth ulceration—Epirubicin—bone cancer	0.000637	0.0051	CcSEcCtD
Azelastine—Influenza like illness—Doxorubicin—bone cancer	0.000633	0.00507	CcSEcCtD
Azelastine—Clemastine—CYP3A4—bone cancer	0.00063	0.616	CrCbGaD
Azelastine—Abnormal vision—Epirubicin—bone cancer	0.000614	0.00492	CcSEcCtD
Azelastine—Mental disability—Epirubicin—bone cancer	0.000611	0.0049	CcSEcCtD
Azelastine—Mouth ulceration—Doxorubicin—bone cancer	0.000589	0.00472	CcSEcCtD
Azelastine—Eczema—Epirubicin—bone cancer	0.000569	0.00456	CcSEcCtD
Azelastine—Abnormal vision—Doxorubicin—bone cancer	0.000568	0.00455	CcSEcCtD
Azelastine—Eye pain—Epirubicin—bone cancer	0.000566	0.00454	CcSEcCtD
Azelastine—Mental disability—Doxorubicin—bone cancer	0.000565	0.00453	CcSEcCtD
Azelastine—Vision blurred—Cisplatin—bone cancer	0.000565	0.00453	CcSEcCtD
Azelastine—Anaphylactoid reaction—Methotrexate—bone cancer	0.000564	0.00452	CcSEcCtD
Azelastine—Ill-defined disorder—Cisplatin—bone cancer	0.000556	0.00446	CcSEcCtD
Azelastine—Increased appetite—Epirubicin—bone cancer	0.000544	0.00436	CcSEcCtD
Azelastine—Malaise—Cisplatin—bone cancer	0.000541	0.00433	CcSEcCtD
Azelastine—Anaphylactoid reaction—Epirubicin—bone cancer	0.000528	0.00423	CcSEcCtD
Azelastine—Eczema—Doxorubicin—bone cancer	0.000526	0.00422	CcSEcCtD
Azelastine—Eye pain—Doxorubicin—bone cancer	0.000524	0.0042	CcSEcCtD
Azelastine—Myalgia—Cisplatin—bone cancer	0.00051	0.00409	CcSEcCtD
Azelastine—Anxiety—Cisplatin—bone cancer	0.000509	0.00408	CcSEcCtD
Azelastine—Discomfort—Cisplatin—bone cancer	0.000504	0.00404	CcSEcCtD
Azelastine—Increased appetite—Doxorubicin—bone cancer	0.000503	0.00403	CcSEcCtD
Azelastine—Face oedema—Epirubicin—bone cancer	0.000494	0.00395	CcSEcCtD
Azelastine—Anaphylactic shock—Cisplatin—bone cancer	0.000489	0.00392	CcSEcCtD
Azelastine—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000489	0.00392	CcSEcCtD
Azelastine—Infection—Cisplatin—bone cancer	0.000486	0.00389	CcSEcCtD
Azelastine—Tachycardia—Cisplatin—bone cancer	0.000478	0.00383	CcSEcCtD
Azelastine—Asthma—Methotrexate—bone cancer	0.000472	0.00378	CcSEcCtD
Azelastine—Nasopharyngitis—Epirubicin—bone cancer	0.000457	0.00366	CcSEcCtD
Azelastine—Face oedema—Doxorubicin—bone cancer	0.000457	0.00366	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000451	0.00361	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000446	0.00357	CcSEcCtD
Azelastine—Asthma—Epirubicin—bone cancer	0.000442	0.00354	CcSEcCtD
Azelastine—Paraesthesia—Cisplatin—bone cancer	0.000439	0.00352	CcSEcCtD
Azelastine—Upper respiratory tract infection—Methotrexate—bone cancer	0.000439	0.00352	CcSEcCtD
Azelastine—Dyspnoea—Cisplatin—bone cancer	0.000436	0.00349	CcSEcCtD
Azelastine—Bronchitis—Epirubicin—bone cancer	0.000425	0.0034	CcSEcCtD
Azelastine—Nasopharyngitis—Doxorubicin—bone cancer	0.000423	0.00339	CcSEcCtD
Azelastine—Pain—Cisplatin—bone cancer	0.000418	0.00335	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000417	0.00334	CcSEcCtD
Azelastine—Upper respiratory tract infection—Epirubicin—bone cancer	0.000411	0.00329	CcSEcCtD
Azelastine—Conjunctivitis—Methotrexate—bone cancer	0.000409	0.00328	CcSEcCtD
Azelastine—Asthma—Doxorubicin—bone cancer	0.000409	0.00328	CcSEcCtD
Azelastine—Pollakiuria—Epirubicin—bone cancer	0.000408	0.00327	CcSEcCtD
Azelastine—Feeling abnormal—Cisplatin—bone cancer	0.000403	0.00323	CcSEcCtD
Azelastine—Weight increased—Epirubicin—bone cancer	0.000402	0.00322	CcSEcCtD
Azelastine—Haematuria—Methotrexate—bone cancer	0.000401	0.00322	CcSEcCtD
Azelastine—Epistaxis—Methotrexate—bone cancer	0.000397	0.00318	CcSEcCtD
Azelastine—Bronchitis—Doxorubicin—bone cancer	0.000393	0.00315	CcSEcCtD
Azelastine—Body temperature increased—Cisplatin—bone cancer	0.000387	0.0031	CcSEcCtD
Azelastine—Conjunctivitis—Epirubicin—bone cancer	0.000383	0.00307	CcSEcCtD
Azelastine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00038	0.00304	CcSEcCtD
Azelastine—Pollakiuria—Doxorubicin—bone cancer	0.000378	0.00303	CcSEcCtD
Azelastine—Haematuria—Epirubicin—bone cancer	0.000376	0.00301	CcSEcCtD
Azelastine—Pharyngitis—Methotrexate—bone cancer	0.000375	0.00301	CcSEcCtD
Azelastine—Weight increased—Doxorubicin—bone cancer	0.000372	0.00298	CcSEcCtD
Azelastine—Epistaxis—Epirubicin—bone cancer	0.000372	0.00298	CcSEcCtD
Azelastine—Sinusitis—Epirubicin—bone cancer	0.00037	0.00296	CcSEcCtD
Azelastine—Visual impairment—Methotrexate—bone cancer	0.000364	0.00292	CcSEcCtD
Azelastine—Hypersensitivity—Cisplatin—bone cancer	0.00036	0.00289	CcSEcCtD
Azelastine—Rhinitis—Epirubicin—bone cancer	0.000355	0.00284	CcSEcCtD
Azelastine—Conjunctivitis—Doxorubicin—bone cancer	0.000354	0.00284	CcSEcCtD
Azelastine—Eye disorder—Methotrexate—bone cancer	0.000353	0.00283	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—bone cancer	0.000352	0.00282	CcSEcCtD
Azelastine—Asthenia—Cisplatin—bone cancer	0.000351	0.00281	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—bone cancer	0.000351	0.00281	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—bone cancer	0.000348	0.00278	CcSEcCtD
Azelastine—Epistaxis—Doxorubicin—bone cancer	0.000344	0.00275	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—bone cancer	0.000342	0.00274	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—bone cancer	0.000341	0.00273	CcSEcCtD
Azelastine—Diarrhoea—Cisplatin—bone cancer	0.000335	0.00268	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—bone cancer	0.000331	0.00265	CcSEcCtD
Azelastine—Flushing—Epirubicin—bone cancer	0.000328	0.00263	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—bone cancer	0.000328	0.00263	CcSEcCtD
Azelastine—Hypoaesthesia—Doxorubicin—bone cancer	0.000326	0.00261	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—bone cancer	0.000325	0.0026	CcSEcCtD
Azelastine—Dysgeusia—Methotrexate—bone cancer	0.000322	0.00258	CcSEcCtD
Azelastine—Back pain—Methotrexate—bone cancer	0.000318	0.00255	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—bone cancer	0.000315	0.00253	CcSEcCtD
Azelastine—Vomiting—Cisplatin—bone cancer	0.000311	0.00249	CcSEcCtD
Azelastine—Vision blurred—Methotrexate—bone cancer	0.00031	0.00248	CcSEcCtD
Azelastine—Rash—Cisplatin—bone cancer	0.000309	0.00247	CcSEcCtD
Azelastine—Dermatitis—Cisplatin—bone cancer	0.000308	0.00247	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—bone cancer	0.000306	0.00245	CcSEcCtD
Azelastine—Ill-defined disorder—Methotrexate—bone cancer	0.000305	0.00245	CcSEcCtD
Azelastine—Flushing—Doxorubicin—bone cancer	0.000304	0.00243	CcSEcCtD
Azelastine—Tension—Epirubicin—bone cancer	0.000302	0.00242	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—bone cancer	0.000301	0.00242	CcSEcCtD
Azelastine—Nervousness—Epirubicin—bone cancer	0.000299	0.0024	CcSEcCtD
Azelastine—Back pain—Epirubicin—bone cancer	0.000298	0.00239	CcSEcCtD
Azelastine—Malaise—Methotrexate—bone cancer	0.000297	0.00238	CcSEcCtD
Azelastine—Vertigo—Methotrexate—bone cancer	0.000296	0.00237	CcSEcCtD
Azelastine—Nausea—Cisplatin—bone cancer	0.000291	0.00233	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—bone cancer	0.00029	0.00232	CcSEcCtD
Azelastine—Cough—Methotrexate—bone cancer	0.000287	0.0023	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—bone cancer	0.000286	0.00229	CcSEcCtD
Azelastine—Agitation—Epirubicin—bone cancer	0.000283	0.00227	CcSEcCtD
Azelastine—Chest pain—Methotrexate—bone cancer	0.00028	0.00224	CcSEcCtD
Azelastine—Myalgia—Methotrexate—bone cancer	0.00028	0.00224	CcSEcCtD
Azelastine—Tension—Doxorubicin—bone cancer	0.00028	0.00224	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—bone cancer	0.000279	0.00223	CcSEcCtD
Azelastine—Malaise—Epirubicin—bone cancer	0.000278	0.00222	CcSEcCtD
Azelastine—Discomfort—Methotrexate—bone cancer	0.000277	0.00222	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—bone cancer	0.000277	0.00222	CcSEcCtD
Azelastine—Vertigo—Epirubicin—bone cancer	0.000277	0.00222	CcSEcCtD
Azelastine—Back pain—Doxorubicin—bone cancer	0.000276	0.00221	CcSEcCtD
Azelastine—Palpitations—Epirubicin—bone cancer	0.000272	0.00218	CcSEcCtD
Azelastine—Confusional state—Methotrexate—bone cancer	0.000271	0.00217	CcSEcCtD
Azelastine—Cough—Epirubicin—bone cancer	0.000269	0.00215	CcSEcCtD
Azelastine—Anaphylactic shock—Methotrexate—bone cancer	0.000269	0.00215	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—bone cancer	0.000268	0.00215	CcSEcCtD
Azelastine—Infection—Methotrexate—bone cancer	0.000267	0.00214	CcSEcCtD
Azelastine—Hypertension—Epirubicin—bone cancer	0.000266	0.00213	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—bone cancer	0.000264	0.00212	CcSEcCtD
Azelastine—Chest pain—Epirubicin—bone cancer	0.000262	0.0021	CcSEcCtD
Azelastine—Myalgia—Epirubicin—bone cancer	0.000262	0.0021	CcSEcCtD
Azelastine—Agitation—Doxorubicin—bone cancer	0.000262	0.0021	CcSEcCtD
Azelastine—Anxiety—Epirubicin—bone cancer	0.000261	0.00209	CcSEcCtD
Azelastine—Discomfort—Epirubicin—bone cancer	0.000259	0.00207	CcSEcCtD
Azelastine—Malaise—Doxorubicin—bone cancer	0.000257	0.00206	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—bone cancer	0.000256	0.00205	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—bone cancer	0.000256	0.00205	CcSEcCtD
Azelastine—Confusional state—Epirubicin—bone cancer	0.000253	0.00203	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—bone cancer	0.000252	0.00202	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—bone cancer	0.000251	0.00201	CcSEcCtD
Azelastine—Infection—Epirubicin—bone cancer	0.00025	0.002	CcSEcCtD
Azelastine—Cough—Doxorubicin—bone cancer	0.000249	0.00199	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—bone cancer	0.000246	0.00197	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—bone cancer	0.000245	0.00196	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000245	0.00196	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—bone cancer	0.000243	0.00194	CcSEcCtD
Azelastine—Myalgia—Doxorubicin—bone cancer	0.000243	0.00194	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—bone cancer	0.000242	0.00194	CcSEcCtD
Azelastine—Paraesthesia—Methotrexate—bone cancer	0.000241	0.00193	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—bone cancer	0.00024	0.00192	CcSEcCtD
Azelastine—Dyspnoea—Methotrexate—bone cancer	0.000239	0.00192	CcSEcCtD
Azelastine—Somnolence—Methotrexate—bone cancer	0.000239	0.00191	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—bone cancer	0.000237	0.0019	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—bone cancer	0.000234	0.00188	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—bone cancer	0.000232	0.00186	CcSEcCtD
Azelastine—Fatigue—Methotrexate—bone cancer	0.000231	0.00185	CcSEcCtD
Azelastine—Infection—Doxorubicin—bone cancer	0.000231	0.00185	CcSEcCtD
Azelastine—Pain—Methotrexate—bone cancer	0.00023	0.00184	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000229	0.00183	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—bone cancer	0.000227	0.00182	CcSEcCtD
Azelastine—Prazepam—CYP3A4—bone cancer	0.000226	0.221	CrCbGaD
Azelastine—Paraesthesia—Epirubicin—bone cancer	0.000226	0.00181	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—bone cancer	0.000224	0.00179	CcSEcCtD
Azelastine—Somnolence—Epirubicin—bone cancer	0.000223	0.00179	CcSEcCtD
Azelastine—Feeling abnormal—Methotrexate—bone cancer	0.000221	0.00177	CcSEcCtD
Azelastine—Gastrointestinal pain—Methotrexate—bone cancer	0.00022	0.00176	CcSEcCtD
Azelastine—Fatigue—Epirubicin—bone cancer	0.000217	0.00174	CcSEcCtD
Azelastine—Constipation—Epirubicin—bone cancer	0.000215	0.00172	CcSEcCtD
Azelastine—Pain—Epirubicin—bone cancer	0.000215	0.00172	CcSEcCtD
Azelastine—Body temperature increased—Methotrexate—bone cancer	0.000212	0.0017	CcSEcCtD
Azelastine—Abdominal pain—Methotrexate—bone cancer	0.000212	0.0017	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000212	0.0017	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—bone cancer	0.000209	0.00167	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—bone cancer	0.000207	0.00166	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—bone cancer	0.000207	0.00166	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—bone cancer	0.000207	0.00166	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—bone cancer	0.000205	0.00165	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—bone cancer	0.0002	0.00161	CcSEcCtD
Azelastine—Constipation—Doxorubicin—bone cancer	0.000199	0.00159	CcSEcCtD
Azelastine—Pain—Doxorubicin—bone cancer	0.000199	0.00159	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—bone cancer	0.000199	0.00159	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—bone cancer	0.000199	0.00159	CcSEcCtD
Azelastine—Hypersensitivity—Methotrexate—bone cancer	0.000198	0.00158	CcSEcCtD
Azelastine—Asthenia—Methotrexate—bone cancer	0.000193	0.00154	CcSEcCtD
Azelastine—Feeling abnormal—Doxorubicin—bone cancer	0.000192	0.00153	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00019	0.00152	CcSEcCtD
Azelastine—Pruritus—Methotrexate—bone cancer	0.00019	0.00152	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—bone cancer	0.000185	0.00148	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—bone cancer	0.000184	0.00147	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—bone cancer	0.000184	0.00147	CcSEcCtD
Azelastine—Diarrhoea—Methotrexate—bone cancer	0.000184	0.00147	CcSEcCtD
Azelastine—Asthenia—Epirubicin—bone cancer	0.00018	0.00144	CcSEcCtD
Azelastine—Pruritus—Epirubicin—bone cancer	0.000178	0.00142	CcSEcCtD
Azelastine—Dizziness—Methotrexate—bone cancer	0.000178	0.00142	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—bone cancer	0.000172	0.00138	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—bone cancer	0.000171	0.00137	CcSEcCtD
Azelastine—Vomiting—Methotrexate—bone cancer	0.000171	0.00137	CcSEcCtD
Azelastine—Rash—Methotrexate—bone cancer	0.000169	0.00136	CcSEcCtD
Azelastine—Dermatitis—Methotrexate—bone cancer	0.000169	0.00136	CcSEcCtD
Azelastine—Headache—Methotrexate—bone cancer	0.000168	0.00135	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—bone cancer	0.000167	0.00134	CcSEcCtD
Azelastine—Dizziness—Epirubicin—bone cancer	0.000166	0.00133	CcSEcCtD
Azelastine—Clozapine—CYP3A4—bone cancer	0.000165	0.162	CrCbGaD
Azelastine—Pruritus—Doxorubicin—bone cancer	0.000164	0.00132	CcSEcCtD
Azelastine—HRH3—Signaling Pathways—GRM4—bone cancer	0.000164	0.00126	CbGpPWpGaD
Azelastine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000161	0.00124	CbGpPWpGaD
Azelastine—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.00016	0.00123	CbGpPWpGaD
Azelastine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.00016	0.00123	CbGpPWpGaD
Azelastine—Vomiting—Epirubicin—bone cancer	0.00016	0.00128	CcSEcCtD
Azelastine—Nausea—Methotrexate—bone cancer	0.000159	0.00128	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—bone cancer	0.000159	0.00127	CcSEcCtD
Azelastine—Rash—Epirubicin—bone cancer	0.000158	0.00127	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—bone cancer	0.000158	0.00127	CcSEcCtD
Azelastine—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000158	0.00121	CbGpPWpGaD
Azelastine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000158	0.00121	CbGpPWpGaD
Azelastine—Headache—Epirubicin—bone cancer	0.000157	0.00126	CcSEcCtD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000157	0.00121	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—GNA11—bone cancer	0.000155	0.00119	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—GRM1—bone cancer	0.000155	0.00119	CbGpPWpGaD
Azelastine—HRH3—GPCR downstream signaling—IL3—bone cancer	0.000154	0.00119	CbGpPWpGaD
Azelastine—Dizziness—Doxorubicin—bone cancer	0.000154	0.00123	CcSEcCtD
Azelastine—KCNH2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000153	0.00117	CbGpPWpGaD
Azelastine—CYP1A1—Biological oxidations—CYP3A4—bone cancer	0.000151	0.00116	CbGpPWpGaD
Azelastine—Nausea—Epirubicin—bone cancer	0.000149	0.0012	CcSEcCtD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000149	0.00115	CbGpPWpGaD
Azelastine—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000149	0.00114	CbGpPWpGaD
Azelastine—Vomiting—Doxorubicin—bone cancer	0.000148	0.00118	CcSEcCtD
Azelastine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000147	0.00113	CbGpPWpGaD
Azelastine—Rash—Doxorubicin—bone cancer	0.000147	0.00117	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—bone cancer	0.000146	0.00117	CcSEcCtD
Azelastine—ADRA1B—LPA receptor mediated events—EGFR—bone cancer	0.000146	0.00112	CbGpPWpGaD
Azelastine—Headache—Doxorubicin—bone cancer	0.000146	0.00117	CcSEcCtD
Azelastine—HRH3—Signaling Pathways—GRM1—bone cancer	0.000142	0.00109	CbGpPWpGaD
Azelastine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000141	0.00108	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—IL3—bone cancer	0.00014	0.00108	CbGpPWpGaD
Azelastine—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.00014	0.00107	CbGpPWpGaD
Azelastine—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000138	0.00106	CbGpPWpGaD
Azelastine—Nausea—Doxorubicin—bone cancer	0.000138	0.00111	CcSEcCtD
Azelastine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000138	0.00106	CbGpPWpGaD
Azelastine—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000137	0.00105	CbGpPWpGaD
Azelastine—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000137	0.00105	CbGpPWpGaD
Azelastine—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000137	0.00105	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000136	0.00105	CbGpPWpGaD
Azelastine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000136	0.00105	CbGpPWpGaD
Azelastine—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000135	0.00104	CbGpPWpGaD
Azelastine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000135	0.00104	CbGpPWpGaD
Azelastine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000134	0.00103	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000134	0.00103	CbGpPWpGaD
Azelastine—KCNH2—Neuronal System—BRAF—bone cancer	0.000132	0.00101	CbGpPWpGaD
Azelastine—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.000129	0.000992	CbGpPWpGaD
Azelastine—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000127	0.000979	CbGpPWpGaD
Azelastine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000127	0.000976	CbGpPWpGaD
Azelastine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000124	0.000949	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000123	0.000941	CbGpPWpGaD
Azelastine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000122	0.000936	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000122	0.000936	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—NDUFA12—bone cancer	0.000122	0.000933	CbGpPWpGaD
Azelastine—ADRA1B—GPCR ligand binding—SMO—bone cancer	0.00012	0.000924	CbGpPWpGaD
Azelastine—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.000118	0.00091	CbGpPWpGaD
Azelastine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000117	0.000897	CbGpPWpGaD
Azelastine—ADRA1B—AMPK Signaling—TP53—bone cancer	0.000116	0.000889	CbGpPWpGaD
Azelastine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000115	0.000881	CbGpPWpGaD
Azelastine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000114	0.000873	CbGpPWpGaD
Azelastine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000113	0.000866	CbGpPWpGaD
Azelastine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000112	0.000861	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—GRM4—bone cancer	0.000111	0.000854	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—RGS1—bone cancer	0.000111	0.000854	CbGpPWpGaD
Azelastine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000111	0.000854	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000111	0.000852	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000111	0.000849	CbGpPWpGaD
Azelastine—KCNH2—Neuronal System—MDM2—bone cancer	0.00011	0.000848	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000109	0.000841	CbGpPWpGaD
Azelastine—HRH1—GPCR ligand binding—SMO—bone cancer	0.000109	0.000836	CbGpPWpGaD
Azelastine—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000106	0.000812	CbGpPWpGaD
Azelastine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000104	0.000801	CbGpPWpGaD
Azelastine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000104	0.000797	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—GRM4—bone cancer	0.000101	0.000776	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—RGS1—bone cancer	0.000101	0.000776	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—GRM4—bone cancer	0.000101	0.000773	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—RGS1—bone cancer	0.000101	0.000773	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—NT5C3A—bone cancer	0.000101	0.000773	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—SMO—bone cancer	9.99e-05	0.000767	CbGpPWpGaD
Azelastine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	9.81e-05	0.000754	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—NDUFA12—bone cancer	9.8e-05	0.000753	CbGpPWpGaD
Azelastine—CYP2D6—Biological oxidations—GSTP1—bone cancer	9.72e-05	0.000747	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—GRM1—bone cancer	9.65e-05	0.000741	CbGpPWpGaD
Azelastine—CYP2C9—Biological oxidations—GSTP1—bone cancer	9.64e-05	0.00074	CbGpPWpGaD
Azelastine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	9.63e-05	0.00074	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—NDUFA12—bone cancer	9.6e-05	0.000738	CbGpPWpGaD
Azelastine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	9.59e-05	0.000737	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—NDUFA12—bone cancer	9.58e-05	0.000736	CbGpPWpGaD
Azelastine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	9.51e-05	0.00073	CbGpPWpGaD
Azelastine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	9.5e-05	0.00073	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.27e-05	0.000712	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.25e-05	0.00071	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—GRM4—bone cancer	9.14e-05	0.000702	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—RGS1—bone cancer	9.14e-05	0.000702	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—GNA11—bone cancer	9.14e-05	0.000702	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—NDUFA12—bone cancer	9.05e-05	0.000695	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—GRM1—bone cancer	8.76e-05	0.000673	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—GRM1—bone cancer	8.73e-05	0.000671	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.69e-05	0.000667	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	8.69e-05	0.000667	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—ATF1—bone cancer	8.49e-05	0.000652	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NDUFA12—bone cancer	8.3e-05	0.000638	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—IL3—bone cancer	8.28e-05	0.000636	CbGpPWpGaD
Azelastine—CYP1A2—Biological oxidations—GSTP1—bone cancer	8.24e-05	0.000633	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—NT5C3A—bone cancer	8.12e-05	0.000624	CbGpPWpGaD
Azelastine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	8.12e-05	0.000624	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.98e-05	0.000613	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—NT5C3A—bone cancer	7.96e-05	0.000611	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—NT5C3A—bone cancer	7.94e-05	0.00061	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—GRM1—bone cancer	7.93e-05	0.000609	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—NT5C3A—bone cancer	7.5e-05	0.000576	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NDUFA12—bone cancer	7.41e-05	0.000569	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NDUFA12—bone cancer	7.23e-05	0.000555	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TGFBR2—bone cancer	7.08e-05	0.000544	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.88e-05	0.000528	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NT5C3A—bone cancer	6.88e-05	0.000528	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NDUFA12—bone cancer	6.81e-05	0.000523	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NDUFA12—bone cancer	6.76e-05	0.000519	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—IGF1R—bone cancer	6.67e-05	0.000512	CbGpPWpGaD
Azelastine—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.36e-05	0.000488	CbGpPWpGaD
Azelastine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.27e-05	0.000482	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—GNA11—bone cancer	6.22e-05	0.000477	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—SMO—bone cancer	6.17e-05	0.000474	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NT5C3A—bone cancer	6.14e-05	0.000472	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NT5C3A—bone cancer	5.99e-05	0.00046	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—GRM4—bone cancer	5.97e-05	0.000458	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—RGS1—bone cancer	5.97e-05	0.000458	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NDUFA12—bone cancer	5.77e-05	0.000443	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NT5C3A—bone cancer	5.65e-05	0.000434	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—GNA11—bone cancer	5.64e-05	0.000434	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—IL3—bone cancer	5.64e-05	0.000433	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—GNA11—bone cancer	5.63e-05	0.000432	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NT5C3A—bone cancer	5.6e-05	0.00043	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—SMO—bone cancer	5.59e-05	0.000429	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	5.55e-05	0.000427	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—GRM4—bone cancer	5.4e-05	0.000415	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—RGS1—bone cancer	5.4e-05	0.000415	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—GRM1—bone cancer	5.17e-05	0.000397	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL3—bone cancer	5.12e-05	0.000393	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—GNA11—bone cancer	5.11e-05	0.000392	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—IL3—bone cancer	5.1e-05	0.000392	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.1e-05	0.000392	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	5.03e-05	0.000386	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.92e-05	0.000378	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—KIT—bone cancer	4.83e-05	0.000371	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NT5C3A—bone cancer	4.78e-05	0.000367	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—GRM1—bone cancer	4.68e-05	0.00036	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL3—bone cancer	4.63e-05	0.000356	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—BRAF—bone cancer	4.54e-05	0.000349	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NDUFA12—bone cancer	4.46e-05	0.000342	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.43e-05	0.00034	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—ENO2—bone cancer	4.41e-05	0.000339	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—EGFR—bone cancer	4.4e-05	0.000338	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—DHFR—bone cancer	4.09e-05	0.000314	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—GNA11—bone cancer	3.82e-05	0.000294	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—MDM2—bone cancer	3.81e-05	0.000292	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.69e-05	0.000284	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SMO—bone cancer	3.65e-05	0.00028	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—ENO2—bone cancer	3.56e-05	0.000273	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ENO2—bone cancer	3.49e-05	0.000268	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.48e-05	0.000268	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ENO2—bone cancer	3.48e-05	0.000267	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CYP3A4—bone cancer	3.47e-05	0.000266	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—GNA11—bone cancer	3.33e-05	0.000256	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—JUN—bone cancer	3.31e-05	0.000254	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—DHFR—bone cancer	3.3e-05	0.000254	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SMO—bone cancer	3.3e-05	0.000253	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ENO2—bone cancer	3.29e-05	0.000252	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—DHFR—bone cancer	3.23e-05	0.000248	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—DHFR—bone cancer	3.23e-05	0.000248	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—MMP9—bone cancer	3.22e-05	0.000247	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ATF1—bone cancer	3.1e-05	0.000238	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—GNA11—bone cancer	3.09e-05	0.000237	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—DHFR—bone cancer	3.05e-05	0.000234	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL3—bone cancer	3.02e-05	0.000232	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—GNA11—bone cancer	3.02e-05	0.000232	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—GNA11—bone cancer	3.02e-05	0.000232	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—GNA11—bone cancer	3.02e-05	0.000232	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ENO2—bone cancer	3.01e-05	0.000231	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—GSTP1—bone cancer	2.97e-05	0.000228	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.93e-05	0.000225	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—GNA11—bone cancer	2.85e-05	0.000219	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ATF1—bone cancer	2.81e-05	0.000216	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CYP3A4—bone cancer	2.8e-05	0.000215	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—DHFR—bone cancer	2.79e-05	0.000215	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CYP3A4—bone cancer	2.74e-05	0.00021	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL3—bone cancer	2.74e-05	0.00021	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CYP3A4—bone cancer	2.73e-05	0.00021	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ENO2—bone cancer	2.69e-05	0.000207	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ENO2—bone cancer	2.62e-05	0.000202	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GNA11—bone cancer	2.61e-05	0.000201	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—EGFR—bone cancer	2.6e-05	0.0002	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	2.59e-05	0.000199	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CYP3A4—bone cancer	2.58e-05	0.000198	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.57e-05	0.000197	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—DHFR—bone cancer	2.49e-05	0.000192	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ENO2—bone cancer	2.47e-05	0.00019	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ENO2—bone cancer	2.45e-05	0.000188	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—DHFR—bone cancer	2.43e-05	0.000187	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IGF1R—bone cancer	2.43e-05	0.000187	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—GSTP1—bone cancer	2.39e-05	0.000184	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CYP3A4—bone cancer	2.37e-05	0.000182	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.36e-05	0.000181	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—GSTP1—bone cancer	2.34e-05	0.00018	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TGFBR2—bone cancer	2.34e-05	0.00018	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—GSTP1—bone cancer	2.34e-05	0.00018	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GNA11—bone cancer	2.33e-05	0.000179	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—DHFR—bone cancer	2.29e-05	0.000176	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GNA11—bone cancer	2.28e-05	0.000175	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—DHFR—bone cancer	2.27e-05	0.000175	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—GSTP1—bone cancer	2.21e-05	0.00017	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IGF1R—bone cancer	2.2e-05	0.000169	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TP53—bone cancer	2.18e-05	0.000168	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GNA11—bone cancer	2.14e-05	0.000165	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GNA11—bone cancer	2.13e-05	0.000163	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CYP3A4—bone cancer	2.11e-05	0.000162	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.1e-05	0.000162	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ENO2—bone cancer	2.1e-05	0.000161	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CYP3A4—bone cancer	2.06e-05	0.000158	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GSTP1—bone cancer	2.03e-05	0.000156	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.94e-05	0.000149	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—DHFR—bone cancer	1.94e-05	0.000149	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.93e-05	0.000148	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.92e-05	0.000147	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GNA11—bone cancer	1.82e-05	0.00014	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GSTP1—bone cancer	1.81e-05	0.000139	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTP1—bone cancer	1.76e-05	0.000136	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KIT—bone cancer	1.76e-05	0.000135	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTP1—bone cancer	1.66e-05	0.000128	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—BRAF—bone cancer	1.66e-05	0.000127	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTP1—bone cancer	1.65e-05	0.000127	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.65e-05	0.000127	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.64e-05	0.000126	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ENO2—bone cancer	1.62e-05	0.000124	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—EGFR—bone cancer	1.61e-05	0.000123	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KIT—bone cancer	1.6e-05	0.000123	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTGS2—bone cancer	1.54e-05	0.000118	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—BRAF—bone cancer	1.5e-05	0.000115	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—DHFR—bone cancer	1.5e-05	0.000115	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—bone cancer	1.45e-05	0.000112	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTP1—bone cancer	1.41e-05	0.000108	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GNA11—bone cancer	1.4e-05	0.000108	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MDM2—bone cancer	1.39e-05	0.000107	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MDM2—bone cancer	1.26e-05	9.66e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTGS2—bone cancer	1.24e-05	9.52e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTGS2—bone cancer	1.21e-05	9.32e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTGS2—bone cancer	1.21e-05	9.3e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—JUN—bone cancer	1.21e-05	9.28e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MMP9—bone cancer	1.17e-05	9.02e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTGS2—bone cancer	1.14e-05	8.79e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—JUN—bone cancer	1.09e-05	8.4e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTP1—bone cancer	1.09e-05	8.35e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MMP9—bone cancer	1.06e-05	8.17e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS2—bone cancer	1.05e-05	8.06e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—bone cancer	9.49e-06	7.29e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS2—bone cancer	9.37e-06	7.19e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS2—bone cancer	9.14e-06	7.02e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS2—bone cancer	8.61e-06	6.62e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—bone cancer	8.59e-06	6.6e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS2—bone cancer	8.54e-06	6.56e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—bone cancer	7.97e-06	6.12e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS2—bone cancer	7.3e-06	5.61e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—bone cancer	7.22e-06	5.54e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS2—bone cancer	5.63e-06	4.33e-05	CbGpPWpGaD
